

# **Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies**

**Effective March 25<sup>th</sup>, 2024**

Certain eligible pharmacies can administer publicly funded COVID-19 vaccines to eligible individuals (see Pharmacy Eligibility below).

The purpose of this Executive Officer (EO) Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies (EO Notice), and the accompanying Frequently Asked Questions (FAQs) document, is to set out the terms and conditions for a participating pharmacy's submission of claims for payment (claims) for administering injectable COVID-19 vaccines to eligible individuals. Each document is a Ministry of Health (ministry) policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators. Participating pharmacies must comply with all terms and conditions set out in the EO Notice and FAQs.

The EO Notice and the accompanying FAQs document are not intended to describe a pharmacy operator's obligations in respect of administering injectable COVID-19 vaccines under applicable legislation, other agreements with the Province of Ontario, or policies of the Ontario College of Pharmacists (OCP). Pharmacy operators with questions about their legal obligations outside of the HNS Subscription Agreement should refer to the applicable legislation, other agreement, or OCP policy as appropriate.

This EO Notice replaces the previous EO Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies that was effective December 22<sup>nd</sup>, 2023.

## **Pharmacy Eligibility**

In order to be eligible to submit claims for administering a publicly funded COVID-19 vaccine, a pharmacy operator (also referred to in this document as a "participating pharmacy") must be authorized by the ministry and meet the following requirements:

- Have a valid HNS Subscription Agreement with the ministry

- Have a valid agreement<sup>a</sup> with the ministry respecting COVID-19 vaccine administration and the use of the Provincial COVID-19 vaccine solution (the “COVID-19 Vaccine Agreement”); and
- Be enrolled in the current Universal Influenza Immunization Program (UIIP)<sup>b</sup>.

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice.

## Individual Eligibility

The following rules are based on the current [COVID-19 Vaccine Guidance](#) (Version 11.0 – March 21, 2024).

An individual is eligible to receive a publicly funded COVID-19 vaccine if they live, work, or study in Ontario or they are visiting Ontario from another province / territory or another country, and if they meet the applicable age and interval and dosing eligibility criteria for a vaccine (see Appendix A, pp.10-12). For all vaccine doses, when eligibility is defined by age, individuals must be the respective age of eligibility on the day of the vaccine administration.

### Individuals who have been previously vaccinated

For individuals who **HAVE been previously vaccinated**, current eligibility criteria differs from the MOH recommendation for the Fall 2023 season. For the Spring 2024 season, in alignment with [NACI](#), individuals who are increased risk of severe illness from COVID-19 may receive an additional dose of an XBB COVID-19 vaccine. **The Ministry of Health is recommending that the following individuals receive an additional dose this spring:**

1. Adults 65 years of age and older
2. Adult residents of long-term care homes and other congregate living settings for seniors
3. Individuals 6 months of age and older who are moderately to severely immunocompromised (due to an underlying condition or treatment)
4. Individuals 55 years and older who identify as First Nations, Inuit, Metis, and other non-Indigenous household members who are 55 years and older

---

<sup>a</sup> A valid agreement is in respect of a particular pharmacy operator operating at a specific pharmacy location. Where a pharmacy is sold, or where a pharmacy operator relocates, a new COVID-19 Vaccine Agreement is required to reflect the new pharmacy operator or location.

<sup>b</sup> Enrollment in the UIIP is in respect of a particular pharmacy operator operating at a specific pharmacy location. Where a pharmacy is sold, or where a pharmacy operator relocates, new enrollment in the UIIP is required to reflect the new pharmacy operator or location.

Receiving a COVID-19 vaccine in Spring 2024 is particularly important for individuals at increased risk of severe illness from COVID-19 who did not receive a dose during the Fall 2023 program. Eligible individuals may receive an XBB COVID-19 vaccine in Spring 2024 if it has been 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection (whichever is later). NACI notes that a shorter interval (3 to < 6 months) can be used to support program implementation (including timing of the Spring 2024 campaign relative to previous and future Fall campaigns).

**All other individuals who have been previously vaccinated are not currently recommended to receive a COVID-19 vaccine dose in Spring 2024 and should wait until further MOH recommendations. This includes individuals who are not at higher risk of severe illness from COVID-19 who did not receive an XBB COVID-19 vaccine in Fall 2023, unless they are specifically recommended to receive a dose by their health care provider.**

Please see Appendices A and B (pp. 10-13) for the recommended vaccination schedule.

For individuals who **have NOT been previously vaccinated** against COVID-19 (for example, children under 5 years requiring primary series or adults with zero doses) are eligible to receive a vaccine from eligible pharmacies. Please refer to Appendix A (pp. 10-12) and Appendix B (pg.13) of this EO Notice for schedule guidelines based on immunization history and immune status for Spring 2024 (adapted from [COVID-19 Vaccine Guidance](#)).

## Individuals who have NOT been previously vaccinated

Individuals who have NOT been previously vaccinated against COVID-19 (for example, children under 5 years requiring primary series or adults with zero doses) continue to be eligible to receive COVID-19 vaccines, please refer to to Appendix A (pp. 10-12) and Appendix B (pg.13) of this EO Notice for schedule guidelines based on immunization history and immune status (adapted from [COVID-19 Vaccine Guidance](#).)

Recommendations include:

i. **Individuals 6 months to 4 years**

- a. Those who are unvaccinated and who are at **high risk of severe illness due to COVID-19 *should* be vaccinated**. In addition to the recommended schedule, **an additional dose is recommended for individuals who are moderately to severely immunocompromised** in order to complete the initial series.
  - For children 6 months to 4 years who are moderately to severely immunocompromised, a 3-dose series of Moderna is likely more acceptable and more feasible due to fewer doses in the schedule.
- b. Those who are unvaccinated and are **not known to be at high risk of severe illness due to COVID-19 *may* be vaccinated**.

- c. **Those who have not completed an appropriate COVID-19 vaccine series** (based on the vaccine product and immune status), should complete the series using the appropriate number of doses using an XBB mRNA COVID-19 vaccine as per [Appendix B](#). Please see [Appendix D](#) for specific scenarios with authorized and recommended intervals for this population.
- ii. **Individuals 5 years and older**
  - a. **Those who are unvaccinated *should* be vaccinated with an XBB COVID-19 vaccine.**
    - i. One dose<sup>c</sup> of an XBB vaccine is recommended. An additional dose is recommended for individuals who are moderately to severely immunocompromised.
    - ii. Unvaccinated individuals 12 years of age and older may receive either an mRNA (Pfizer or Moderna) or protein subunit (Novavax) COVID-19 vaccine. Note that there is significantly more effectiveness data available for the mRNA XBB vaccines compared to the Novavax XBB vaccine.

As per NACI - individuals will likely be unaware of their recent infection status as testing is no longer widespread and many individuals, particularly children, may experience mild or no symptoms. Those who do have a known recent SARS-CoV-2 infection who are not previously vaccinated or have not completed a primary series may consider delaying COVID-19 vaccination by 8 weeks if the individual is not moderately to severely immunocompromised, or by 4 to 8 weeks if the individual is moderately to severely immunocompromised.

## Other eligibility information

Informed consent is required to administer any COVID-19 vaccine to an eligible individual. Please refer to the most up to date version of [COVID-19 Vaccine Guidance](#) for detailed information on vaccine recommendations, recommendations for moderately to severely immunocompromised individuals, recommendations regarding re-vaccination with a new COVID-19 vaccine series post transplantation, out of province vaccines, etc.

Note: To align with National Advisory Committee on Immunization (NACI) and the product monographs, as of Fall 2023, the Ontario Ministry of Health (MOH) is moving away from using the terms 'primary series' and 'booster dose(s)'. This document refers to an individual's vaccination status as '**not previously vaccinated**' and '**previously vaccinated**' (refer to current version of the [COVID-19 Vaccine Guidance](#) for details).

---

<sup>c</sup> While the authorized schedule is 2 doses for Novavax XBB, NACI recommends that unvaccinated individuals who are not immunocompromised may follow a 1-dose schedule.

## Claims for Payment

- There is no cost to eligible patients who receive the COVID-19 vaccine when administered at a pharmacy.
- For each valid claim submitted, a pharmacy will receive \$13.00 as payment for providing the following services:
  - Providing the patient with details of the process and answering any questions related to the vaccination.
  - Obtaining the consent of the patient or their substitute decision-maker prior to vaccine administration
  - Administering the COVID-19 vaccine.
  - Providing the patient with proper monitoring and written vaccine information as well as after-care instructions following vaccine administration.
  - Providing the patient with a written receipt of the vaccination with the pharmacy contact information **after** the vaccine is administered (see Pharmacy Documentation Requirements section below); a pharmacy may wish to issue an electronic receipt as well. (Note: a written receipt can be printed from COVAX<sub>ON</sub>).
  - Complying with any requirements to access and use the Provincial COVID-19 Vaccine Solution-COVAX<sub>ON</sub> under the COVID-19 Vaccine Agreement.
- Pharmacies may access personal protective equipment (PPE) from the ministry's dedicated supply, if needed, to administer the COVID-19 vaccine. The ministry's supply of PPE must **ONLY** be used to support the activity of pharmacies administering the publicly funded COVID-19 vaccine.
- The table in Appendix C lists the publicly funded COVID-19 vaccines that are available to pharmacies and are billable, including any restrictions on administering the vaccine (e.g., age groups).

## Exclusions and Restrictions

- If a patient does not have a valid Ontario health card number, pharmacy staff can still administer the publicly funded COVID-19 vaccine, provided that the patient provides an alternate identification confirming their name and date of birth. In such cases, pharmacies must use the proxy patient ID: 79999 999 93.
- Administration of non-publicly funded COVID-19 vaccines that are privately purchased by the pharmacy does not qualify for payment.

- Vaccine administration must occur at the location of the participating pharmacy premises, unless otherwise indicated. The pharmacy is permitted to administer publicly funded vaccines supplied by their distributor in a nearby location (e.g., an adjacent pharmacy parking lot) and retirement homes, elderly congregate settings, long-term care homes, or mobile clinic locations as long as they are able to ensure adherence to public safety and relevant Ministry policy / direction (including infection prevention and control measures), the COVID-19 Vaccine Agreement, and any Ontario College of Pharmacist (OCP) standards, policies or guidelines. See the most recent version of the accompanying FAQs for more information.
- The role of pharmacists, pharmacy students, interns or pharmacy technicians administering the COVID-19 vaccine in initiatives led by other authorized organizations that have entered into COVID-19 Vaccine Agreements with the Ministry (e.g., public health units or hospitals that organize mass immunization clinics) that are not billed through the HNS is excluded from this notice.
- A pharmacist’s recommendation to a prescriber that a patient should receive a COVID-19 vaccine is not a billable service under the Pharmaceutical Opinion Program.

## Billing Procedures – Summary

- Claims for administering the publicly funded COVID-19 vaccine can only be submitted electronically using the HNS (see “Billing Procedures - Detailed” below). No manual paper claims will be accepted unless 3 intervention codes are required in order to process the claim.
- The Part A pharmacist who administers the vaccine or who is overseeing other pharmacy staff administering the vaccine must be identified in the prescriber field on the claim. Each claim must include the Drug Identification Number (DIN) corresponding to the publicly funded COVID-19 vaccine that was administered to the eligible individual (see table in Appendix C).
- The person submitting the claim must ensure that the eligible individual’s date of birth, Ontario health number and name (as it appears on the health card / document) are included in the claim. Failure to do so – especially for non-Ontario Drug Benefit (ODB) Program recipients – may impact the ability to submit future claims for these individuals.

- **For eligible individuals without an Ontario health number, pharmacies must use the proxy patient ID: 79999 999 93 (see below for further details).**

## Billing Procedures – Detailed

The claim submission follows the usual process (See [Section 5.1](#) of the Ontario Drug Program Reference Manual) for submitting claims in the HNS with the following additional information:

### **Fields required for all claims for pharmacist administered COVID-19 vaccines**

#### **ODB recipients and non-ODB recipients**

- Intervention code 'PS': (Professional Care Services)
- Drug Identification Number (DIN): as per the publicly funded COVID-19 vaccine administered (see Appendix C)
- Valid Pharmacist ID
- Professional fee: \$13.00

#### **Additional fields required for non-ODB recipients with an Ontario health number**

When submitting a claim for an eligible individual who does not have ODB coverage, submit the following additional information:

- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Patient's Ontario Health number
- Intervention codes:
  - PS: Professional Care Services
  - ML: Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)
- Carrier ID: 'S'
- Drug Identification Number (DIN): as per the publicly funded COVID-19 vaccine administered
- Valid Pharmacist ID

#### **Additional fields required for non-ODB recipients without an Ontario health number**

When submitting a claim for an eligible individual who does not have an Ontario health number, submit the following additional information:

- First Name: Patient's first name
- Last Name: Patient's last name

- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Proxy patient ID: 79999 999 93
- Intervention codes:
  - PS: Professional Care Services
  - PB: Name entered is consistent with card
- Valid Pharmacist ID

**Payment for epinephrine auto-injector for emergency treatment after administration of the COVID-19 vaccine**

If there is an adverse event resulting immediately after pharmacy staff administers a publicly funded COVID-19 vaccine, the ministry will reimburse pharmacies for the acquisition cost of the epinephrine auto-injector up to the total amount reimbursed.

Emergency treatment must take place in the pharmacy or where the vaccine was administered, for example an adjacent pharmacy parking lot, retirement home, long-term care home, other congregate setting, or mobile clinic location, if applicable.

The claim submission process is the same as the one followed for the publicly funded UIIP. Refer to [Section 6.15](#) of the Ontario Drug Program Reference Manual for billing information.

**Pharmacy Documentation Requirements**

Pharmacies must keep a record of every dose of publicly funded COVID-19 vaccine administered.

Pharmacists shall keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act*, the COVID-19 Vaccine Agreement, and any instructions or guidelines provided by the OCP or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for administering a publicly funded COVID-19 vaccine must be maintained in a readily available format for the purpose of ministry inspection for a minimum of 10 years from the last recorded pharmacy service provided to the patient, or until 10 years after the day on which the patient reached or would have reached the age of 18 years, whichever is longer.

Overpayments due to inappropriate claim submissions are subject to recovery.

Pharmacy documentation must be maintained in a readily retrievable format and record requirements are:

- Record of name and address of patient.
- Record of patient's Ontario health number or alternate ID with contact information if applicable.



- Record of name of vaccine administered, dose (including half-dosing if applicable), lot number, expiry date, time, date, route and site of administration.
- Record of pharmacy name, pharmacy address and name and signature of individual who administered the vaccine.
- Record of location of administration (inside pharmacy, pharmacy parking lot or within the retirement home, elderly congregate setting, long-term care home or location of a mobile clinic if applicable)
- Evidence of the provision of a written and electronic (if applicable) record (post administration) of the COVID-19 immunization record to the patient, which includes the pharmacy’s contact information and date and time for the second scheduled dose at the same pharmacy location. Note: date and time of the second dose may be hand-written on the written record provided to the patient.
- Record of any serious adverse events following immunization that result in the administration of epinephrine, and the circumstances relating to the administration of the substance.
- Records documenting compliance with any requirements to access and use the Provincial COVID-19 Vaccine Solution-COVAXON under the COVID-19 Vaccine Agreement. Note: All respective health care providers whether pharmacist, intern, registered pharmacy student, pharmacy technician or other health care provider must identify themselves as the vaccinator in the COVAX<sub>ON</sub> system and on the vaccine receipt provided to the patient.

## Prior EO Notices

Updates relating to this Executive Officer Notice were, prior to April 6, 2023, communicated as two (2) separate EO Notices (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**; Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Billing**) on the effective dates listed below.

EO Notices in 2024				
March 25				
EO Notices in 2023				
March 6	July 7	October 13		
April 6	September 26	December 22		
EO Notices in 2022				
January 13	April 7	July 28	September 12	November 8
February 18	May 2	August 8	September 26	December 21

March 25	July 14	September 1	October 17	
<b>EO Notices in 2021</b>				
March 10	May 11	June 4	September 1	December 2
March 22	May 13	June 14	September 8	December 17
April 1	May 18	June 17	October 1	December 20
April 19	May 21	June 25	October 8	
April 30	May 23	July 5	November 3	
May 6	May 31	August 18	November 25	

**Additional Information:**

**For pharmacy billing:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

**For COVID-19 vaccine rollout in pharmacy:**

Please email the ministry at: [OPDPInfoBox@ontario.ca](mailto:OPDPInfoBox@ontario.ca)

**For Ministry COVID-19 Vaccine-Relevant Information and Planning Resources**

Please access this [website](#)

**For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-428

**Appendix A: mRNA COVID-19 Vaccine Schedule Based on Immunization History and Immune Status for Spring 2024 (adapted from Appendix B in the [COVID-19 Vaccine Guidance](#))**

**A. Individuals who are NOT moderately to severely immunocompromised**

**(i) Age: 6 Months – 4 years NOT moderately to severely immunocompromised**

COVID-19 Immunization History <sup>1</sup>	Recommended Number of COVID-19 Vaccine Doses and Interval <sup>2</sup> Between Doses (6 months to 4 years)	
	Moderna Schedule	Pfizer Schedule
3 or more doses	Vaccine series complete, no further doses recommended at this time.	Vaccine series complete, no further doses recommended at this time.
2 doses	Vaccine series complete, no further doses recommended at this time.	<b>1 dose</b> <ul style="list-style-type: none"> <li>• Recommended: <b>56 days</b> from last dose</li> <li>• Minimum:               <ul style="list-style-type: none"> <li>○ 28 days from last dose (if 2<sup>nd</sup> dose was Moderna)</li> <li>○ 56 days from last dose (if 2<sup>nd</sup> dose was Pfizer)</li> </ul> </li> </ul>
1 dose	<b>1 dose</b> <ul style="list-style-type: none"> <li>• Recommended: <b>56 days</b> from last dose</li> <li>• Minimum: 28 days from last dose<sup>3</sup></li> </ul>	<b>2 doses</b> <ul style="list-style-type: none"> <li>• Recommended: <b>56 days</b> from last dose and between doses</li> <li>• Minimum:               <ul style="list-style-type: none"> <li>○ 28 days from last dose (if 1<sup>st</sup> dose was Moderna) and between doses</li> <li>○ If 1<sup>st</sup> dose was Pfizer:                   <ul style="list-style-type: none"> <li>▪ 21 days between dose 1 &amp; 2</li> <li>▪ 56 days between dose 2 &amp; 3</li> </ul> </li> </ul> </li> </ul>
0 doses	<b>2 doses</b> <ul style="list-style-type: none"> <li>• Recommended: <b>56 days</b> between doses</li> <li>• Minimum: 28 days between doses<sup>3</sup></li> </ul>	<b>3 doses</b> <ul style="list-style-type: none"> <li>• Recommended: <b>56 days</b> between doses</li> <li>• Minimum:               <ul style="list-style-type: none"> <li>○ 21 days between dose 1 &amp; 2</li> <li>○ 56 days between dose 2 &amp; 3</li> </ul> </li> </ul>

**(ii) Age: 5 years and older NOT moderately to severely immunocompromised**

- If **previously vaccinated** - no doses are recommended in Spring 2024, unless recommended by a health care provider.
- If **previously unvaccinated** - may receive one dose as recommended in the product monographs.

<sup>1</sup> Denotes of a history of any COVID-19 vaccines including the XBB formulation.

<sup>2</sup> Recommended intervals are based on NACI recommendations. A longer interval between doses of a COVID-19 vaccine, results in a more robust and durable immune response and higher vaccine effectiveness. The minimum interval is the shortest interval at which the product should be given and is outlined in the product monographs.

<sup>3</sup> The recommended interval is 6 months from the last COVID-19 vaccine dose. However, a shorter interval of at least 3 months may be used, to support implementation (including timing of the spring campaign relative to previous and future fall campaigns)

**B. For individuals who are moderately to severely immunocompromised**

**(i) Age: 6 Months – 4 Years who ARE moderately to severely immunocompromised**

COVID-19 Immunization History <sup>4</sup>	Recommended Number of COVID-19 Vaccine Doses and Interval <sup>5</sup> Between Doses (for individuals age 6 months to 4 years who are moderately to severely immunocompromised)	
	Moderna Schedule	Pfizer Schedule
4 or more doses	<b>1 dose</b> <ul style="list-style-type: none"> <li>Recommended: <b>168 days</b> from last dose</li> <li>Minimum: 84 days from last dose<sup>6</sup></li> </ul>	<b>1 dose</b> <ul style="list-style-type: none"> <li>Recommended: <b>168 days</b> from last dose</li> <li>Minimum: 84 days from last dose<sup>6</sup></li> </ul>
3 doses	<b>1 dose</b> <ul style="list-style-type: none"> <li>Recommended: <b>168 days</b> from last dose</li> <li>Minimum: 84 days from last dose<sup>6</sup></li> </ul>	<b>1 dose</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> from last dose</li> <li>Minimum: <ul style="list-style-type: none"> <li>28 days from last dose (if 3<sup>rd</sup> dose was Moderna)</li> <li>56 days from last dose (if 3<sup>rd</sup> dose was Pfizer)</li> </ul> </li> </ul>
2 doses	<b>1 dose</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> from last dose</li> <li>Minimum: 28 days from last dose<sup>6</sup></li> </ul> <i>Moderna preferred<sup>7</sup></i>	<b>2 doses</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> from last dose and between doses</li> <li>Minimum: <ul style="list-style-type: none"> <li>28 days from last dose (if 2<sup>nd</sup> dose was Moderna)</li> <li>If 2<sup>nd</sup> dose was Pfizer <ul style="list-style-type: none"> <li>56 days between dose 2 &amp; 3</li> <li>56 days between dose 3 &amp; 4</li> </ul> </li> </ul> </li> </ul>
1 dose	<b>2 doses</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> from last dose and between doses</li> <li>Minimum: 28 days from last dose and between doses<sup>6</sup></li> </ul> <i>Moderna preferred<sup>7</sup></i>	<b>3 doses</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> from last dose and between doses</li> <li>Minimum: <ul style="list-style-type: none"> <li>28 days from last dose (if 1<sup>st</sup> dose was Moderna)</li> <li>If 1<sup>st</sup> dose was Pfizer <ul style="list-style-type: none"> <li>21 days between dose 1 &amp; 2</li> <li>56 days between dose 2 &amp; 3</li> <li>56 days between dose 3 &amp; 4</li> </ul> </li> </ul> </li> </ul>
0 doses	<b>3 doses</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> between doses</li> <li>Minimum: 28 days between doses<sup>6</sup></li> </ul> <i>Moderna preferred<sup>7</sup></i>	<b>4 doses</b> <ul style="list-style-type: none"> <li>Recommended: <b>56 days</b> between doses</li> <li>Minimum: <ul style="list-style-type: none"> <li>21 days between dose 1 &amp; 2</li> <li>56 days between dose 2 &amp; 3</li> <li>56 days between dose 3 &amp; 4</li> </ul> </li> </ul>

<sup>4</sup> Denotes of a history of any COVID-19 vaccines including the XBB formulation.

<sup>5</sup> Recommended intervals are based on NACI recommendations. A longer interval between doses of a COVID-19 vaccine, results in a more robust and durable immune response and higher vaccine effectiveness. The minimum interval is the shortest interval at which the product should be given and is outlined in the vaccine product monographs.

<sup>6</sup> The recommended interval is 6 months from the last COVID-19 vaccine dose. However, a shorter interval of at least 3 months may be used, to support implementation (including timing of the spring campaign relative to previous and future fall campaigns)

<sup>7</sup> For children 6 months to 4 years who are moderately to severely immunocompromised, a 3-dose series of Moderna is likely more acceptable and more feasible due to fewer doses in the schedule compared to the 4-dose series of Pfizer.

(ii) Age: 5 years and older *who ARE moderately to severely immunocompromised*

- If **previously vaccinated** - may receive a Spring 2024 COVID-19 vaccine, please see [Vaccine Recommendations](#) section (in COVID-19 Vaccine Guidance) for eligibility.
- If **previously unvaccinated** – should receive two doses as recommended in the product monographs.

**Appendix B: Novavax XBB Schedule Based on Immunization History and Immune Status for Spring 2024 (adapted from Appendix C in the [COVID-19 Vaccine Guidance](#))**






**A. For individuals who are NOT moderately to severely immunocompromised aged 12 years and older**

- If **previously vaccinated** - no doses are recommended in Spring 2024, unless recommended by a health care provider.
- If **previously unvaccinated** – as per [NACI](#), should receive one dose. While the authorized schedule is 2 doses, NACI recommends that unvaccinated individuals who are not immunocompromised and receiving Novavax XBB may follow a 1-dose schedule.

**B. For individuals who are moderately to severely immunocompromised aged 12 years and older**

- If **previously vaccinated** - may receive a Spring 2024 COVID-19 vaccine, please see [Vaccine Recommendations section](#) (in COVID-19 Vaccine guidance) section for eligibility
- If **previously unvaccinated** – should receive a minimum of 2 doses as per [NACI](#).

**Appendix C: COVID-19 Vaccines Available for Use in Ontario (adapted from Appendix A of [COVID-19 Vaccine Guidance](#))**

COVID-19 Formulations	Moderna XBB			Pfizer-BioNTech XBB	Pfizer-BioNTech XBB	Pfizer-BioNTech XBB	Novavax XBB
Cap and Label Colour							
	Royal blue cap and coral blue label			Maroon cap and label	Blue cap and label	Grey cap and label	Royal blue cap
Authorized Age Group	6 mo - 4 yrs	5-11 yrs	12 yrs+	6 months - 4 years	5 - 11 yrs	12 yrs+	12 yrs+
Vial Concentration	0.1 mg/mL			0.015 mg/mL	0.03 mg/mL	0.1 mg/mL	0.01 mg/mL
Dose/ Volume	25 mcg/ 0.25 mL	25 mcg/ 0.25 mL	50 mcg/ 0.5 mL	3 mcg/0.2 mL	10 mcg/0.3 mL	30 mcg/ 0.3mL	5 mcg/0.5 mL
Dilution	None			2.2 mL/vial	None	None	None
Vaccine Type	Monovalent mRNA			Monovalent mRNA	Monovalent mRNA	Monovalent mRNA	Protein Subunit Vaccine
Use	Unvaccinated and previously vaccinated individuals			Unvaccinated and previously vaccinated individuals	Unvaccinated and previously vaccinated individuals	Unvaccinated and previously vaccinated individuals	Unvaccinated and previously vaccinated individuals
DIN Number	02541270			02541866	02541858	02541823	02543656
Product Monograph	<a href="#">Moderna XBB.1.5</a>			<a href="#">Pfizer XBB.1.5</a>	<a href="#">Pfizer XBB.1.5</a>	<a href="#">Pfizer XBB.1.5</a>	<a href="#">Novavax XBB.1.5</a>

\*Please ensure to use correct inventory product name in COVaxON and DIN# claims in HNS